Literature DB >> 9678227

People with mental retardation have an increased prevalence of osteoporosis: a population study.

J Center1, H Beange, A McElduff.   

Abstract

Prevalence of and risk factors for osteoporosis in a community population of 94 young adults with mental retardation was examined. Results show lower bone mineral density in this group than in an age-matched reference population. Factors associated with low bone mineral density included small body size, hypogonadism, and Down syndrome in both genders and a high phosphate level in females. Low vitamin D levels were common in both genders, despite high levels of exposure to sunshine. A history of fracture was also common. Low bone mineral density and fracture were associated in females but not males. Because morbidity following fracture is likely to be more serious in this population, further investigation of osteoporosis and prevention strategies for both osteoporosis and fractures are important.

Entities:  

Mesh:

Year:  1998        PMID: 9678227     DOI: 10.1352/0895-8017(1998)103<0019:PWMRHA>2.0.CO;2

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  23 in total

1.  Bone mineral mass in males and females with and without Down syndrome.

Authors:  Fatima Baptista; Ana Varela; Luis B Sardinha
Journal:  Osteoporos Int       Date:  2004-09-09       Impact factor: 4.507

2.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

3.  Disruption of bone development and homeostasis by trisomy in Ts65Dn Down syndrome mice.

Authors:  Joshua D Blazek; Anna Gaddy; Rachel Meyer; Randall J Roper; Jiliang Li
Journal:  Bone       Date:  2010-09-24       Impact factor: 4.398

Review 4.  Screening tests for adults with intellectual disabilities.

Authors:  Joanne E Wilkinson; Larry Culpepper; Mary Cerreto
Journal:  J Am Board Fam Med       Date:  2007 Jul-Aug       Impact factor: 2.657

5.  Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.

Authors:  Megan Stringer; Irushi Abeysekera; Jared Thomas; Jonathan LaCombe; Kailey Stancombe; Robert J Stewart; Karl J Dria; Joseph M Wallace; Charles R Goodlett; Randall J Roper
Journal:  Physiol Behav       Date:  2017-05-03

6.  Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities.

Authors:  Kathleen C Watson; Martha J Lentz; Kevin C Cain
Journal:  Womens Health Issues       Date:  2006 Nov-Dec

7.  Fracture risk in people with developmental disabilities: results of a large claims data analysis.

Authors:  G Büchele; C Becker; I D Cameron; R Auer; D Rothenbacher; H H König; K Rapp
Journal:  Osteoporos Int       Date:  2016-08-24       Impact factor: 4.507

8.  Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

Authors:  Irushi Abeysekera; Jared Thomas; Taxiarchis M Georgiadis; Alycia G Berman; Max A Hammond; Karl J Dria; Joseph M Wallace; Randall J Roper
Journal:  Mol Nutr Food Res       Date:  2016-02-11       Impact factor: 5.914

9.  Bone mass and density in preadolescent boys with and without Down syndrome.

Authors:  J Wu
Journal:  Osteoporos Int       Date:  2013-05-17       Impact factor: 4.507

Review 10.  Endocrine and musculoskeletal abnormalities in patients with Down syndrome.

Authors:  Yousra Hawli; Mona Nasrallah; Ghada El-Hajj Fuleihan
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.